A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
Gastric Cancer Mar 06, 2018
Lu Z, et al. - The efficacy and safety of paclitaxel/capecitabine therapy were assessed, followed by capecitabine for maintenance (PACX) versus cisplatin/capecitabine therapy (XP) in advanced gastric cancer. First-line chemotherapy with PACX was effective with milder toxicities in advanced gastric cancer; however, PACX cannot replace XP.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
